Skip to main content
TNGX
NASDAQ Life Sciences

Major Investor Files to Sell $113M in TNGX Stock, Following $105M in Recent Sales

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$31.25
Mkt Cap
$5.257B
52W Low
$4.6
52W High
$34.39
52W Position info
579% above low
Off High info
9.1% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

TNGX has more than doubled off its 52-week low of $4.6.

Summary

A former affiliate and major investor, Nextech Crossover I SCSp, has filed to sell an additional $113.4 million in Tango Therapeutics stock, following $105.1 million in sales over the past three months.


Key Events · Ownership and Investor Activity · TNGX

  • Major Investor Files to Sell

    Nextech Crossover I SCSp, identified as a former affiliate, has filed a Form 144 to sell 3,766,081 shares of common stock.

  • Significant Proposed Sale Value

    The proposed sale is valued at approximately $113,359,038.00, representing 2.15% of the company's market capitalization.

  • Follows Recent Large Sales

    This filing follows sales of 3,500,000 shares for gross proceeds of $105,052,300.00 by the same entity within the last three months.

  • Substantial Liquidation

    The combined sales and proposed sales by Nextech Crossover I SCSp total over $218 million, indicating a significant reduction of their stake in the company.


Analysis · TNGX · Life Sciences

Nextech Crossover I SCSp, a former affiliate and significant investor, has filed to sell an additional $113.4 million worth of Tango Therapeutics stock. This follows recent sales of $105.1 million by the same entity in the past three months, indicating a substantial and ongoing liquidation of their position. This large-scale selling by a major investor, especially after recent positive clinical data and a significant public offering, can create considerable selling pressure and suggests a lack of long-term conviction at current valuations.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TNGX was trading at $31.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3B. The 52-week trading range was $4.60 to $34.39. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TNGX - Latest Insights

TNGX
Nov 09, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $21.82
Real-time Price: $23.15 info
Change: +$1.33 (+6%) info
Market Cap: $3.747B info
TNGX
Oct 23, 2026, 7:01 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $29.13
Real-time Price: $23.15 info
Change: -$5.98 (-21%) info
Market Cap: $3.747B info
TNGX
Oct 23, 2026, 6:36 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $31.85
Real-time Price: $23.15 info
Change: -$8.70 (-27%) info
Market Cap: $3.747B info
TNGX
Oct 23, 2026, 6:30 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $32.06
Real-time Price: $23.15 info
Change: -$8.91 (-28%) info
Market Cap: $3.747B info
TNGX
Aug 11, 2026, 5:10 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $26.45
Real-time Price: $23.15 info
Change: -$3.30 (-12%) info
Market Cap: $3.747B info